Piper Sandler analyst David Westenberg lowered the firm’s price target on Adaptive Biotechnologies to $14 from $15 and keeps an Overweight rating on the shares. The analyst updated the company’s model post the earnings report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADPT:
- Cathie Wood’s ARK Investment bought 383.8K shares of Adaptive Biotechnologies
- Adaptive Biotechnologies management to meet virtually with Piper Sandler
- Adaptive Biotechnologies sees FY23 revenue $205M-$215M, consensus $207.17M
- Adaptive Biotechnologies announces the departure Sood, CCO of the MRD business
- Adaptive Biotechnologies reports Q2 EPS (33c), consensus (35c)